Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
APAprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE)

NASDAQ Global Select · Currency in USD
$0.45 ▼ -0.07 (-13.27%)
At close: Oct 26, 4:00 PM ET. Market closed.
$0.45 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:10 PM ET

Summary

Previous Close
$0.52
Open
$0.43
Day's Range
$0.41 – $0.46
52 Week Range
$0.41 – $1.49
Volume
568,600
Avg. Volume
232,049
Market Cap
$5.65M
Beta (5Y Monthly)
1.63
PE Ratio (TTM)
--
EPS (TTM)
-$0.23
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Aprea Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
8
CEO
Oren Gilad
Website
aprea.com

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$0.08 · Revenue est. $307.50K
DateEst.Actual
Aug 12, 2026-$0.18-$0.07Beat
May 13, 2026-$0.23-$0.22Beat
Mar 16, 2026-$0.38-$0.32Beat
Nov 12, 2025-$0.11-$0.47Miss
Aug 12, 2025-$0.77-$0.53Beat
May 14, 2025-$0.65-$0.66Miss

Analyst view

Rating: Buy
Buy 50% · Hold 25% · Sell 25%

Get free alerts on APRE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.